Granules American subsidiary clears US FDA audit

15 Mar 2022 , 01:31 PM

The GPI facility was inspected by the US FDA from 24th to 28th January 2022 for two of its product applications filed. There were three minor observations during the inspection and GPI had addressed the observations in the stipulated time period.

Commenting on the audit, Priyanka Chigurupati, executive director, GPI, said ?We are glad to have completed yet another audit after successfully addressing minor observations. This is the sixth successful US FDA audit for this facility.?

Hyderabad-based Granules India is a vertically integrated fast growing Indian pharmaceutical company. It is present in the manufacturing of entire value chain – from active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs).

The drug maker reported a 31.2% fall in consolidated net profit to Rs 101 crore in Q3 FY22 from Rs 147 crore posted in Q3 FY21. Consolidated Income from operations grew by 18% year on year to Rs 997 crore in Q3 FY22 as compared to Rs 845 crore posted in Q3 FY21.

The scrip advanced 0.03% to currently trade at Rs 302.90 on the BSE.

Powered by Capital Market – Live News